CHEMIFY
Design, optimise and synthesise.
Chemify designed potential hits, explored chemical series and synthesised compounds for experimental evaluation.
Let’s talkCASE STUDY / TUBERCULOSIS DISCOVERY
Chemify and Lgenia advanced one tuberculosis programme to hit-to-lead entry and improved potency in a second, connecting computational design, synthesis and partner-led assays with support from the Gates Foundation.
Chemify × Lgenia
Two priority tuberculosis targets
Gates Foundation
01THE BRIEF
Match the activity of known inhibitors while improving drug-like properties.
That brief guided exploration across multiple chemical series and two priority tuberculosis targets. Molecular design considered biological activity, medicinal chemistry properties and the practicality of synthesis together.
02 / THE EXPERIMENTS
Computational design and physical compounds connected through partner-led assays.
CHEMIFY
Chemify designed potential hits, explored chemical series and synthesised compounds for experimental evaluation.
LGENIA
Lgenia supplied structural and background information on the targets and led compound testing in the relevant project-specific assays.
03 / THE RESULTS
Two target programmes. Distinct advances in each.
TARGET 1
>2505% met the programme-defined potency goals.
The programme progressed from hit identification to the entry point for hit-to-lead development.
TARGET 2
~100Several-fold improvement in potency within one chemical series.
The result identified an improved series to inform further optimisation.
04WHAT THE PROGRAMME CREATED
The value is in the compounds and the evidence they create.
For Target 1, the programme reached the entry point for hit-to-lead development. For Target 2, the potency improvement provides a basis for deciding which chemistry to optimise next.
Together, the synthesis work and Lgenia’s assay findings help the teams decide which compounds to pursue, which series to refine and what the next experiment needs to resolve.
Shape your discovery programmeThis earlier published case study focused on Mtb NadE. Known inhibitors had solubility and permeability limitations. Chemify synthesised 12 reference compounds and designed 28 analogues in the first cycle, using structural and pharmacophore modelling to inform the next search.
Generated computationally for further filtering.
Remaining candidates then ranked in three dimensions.
Across 14 core scaffolds in cycles two and three.
Chemify reported improved solubility and permeability relative to the starting series.
The two-target programme update is presented separately from the earlier published Mtb NadE example.
Explore ways we work